Aurobindo, Cipla and Viatris’s Mylan will be able to produce generic versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis to be made available in least developed, low-income, lower-middle-income and sub-Saharan African countries, under licensing deals that the three firms have signed with the Medicines Patent Pool.
The announcement of the three sub-licensees comes after the MPP last year invited expressions of interest from potential partners based...